Recent developments in lipid-based pharmaceutical nanocarriers

Purpose: Lipid-based nanocarriers such as liposomes and micelles can protect drugs, reduce nonspecific toxicity, and improve pharmacokinetics, but conventional formulations are limited by rapid clearance, poor targeting, and inefficient intracellular delivery. Engineering “multifunctional pharmaceutical nanocarriers” that combine longevity, targeting, stimuli-sensitivity, and imaging could significantly improve therapeutic and diagnostic protocols.

Hypothesis: If liposomes and micelles are engineered with optimized lipid/polymer composition, PEG shielding, targeting ligands, stimuli-responsive components, cell-penetrating peptides, and/or contrast agents, then they can achieve prolonged circulation, passive and active targeting to pathological sites, triggered drug release, enhanced intracellular delivery, and simultaneous therapy and imaging.

Aims: Review properties and applications of lipid-based nanocarriers, focusing on liposomes and micelles. - Describe long-circulating, targeted, immunotargeted, pH-sensitive, and cell-penetrating peptide–modified liposomes. - Summarize polymeric and lipid-core micelles, drug loading/solubilization, and targeting strategies. - Highlight clinical applications, diagnostic imaging, siRNA delivery, and immunological uses. - Discuss future directions for multifunctional nanocarriers.

Delivery system: Liposomes: plain liposomes; PEGylated long-circulating liposomes; targeted liposomes including immunoliposomes, transferrin- and folate-targeted liposomes; pH-sensitive liposomes; CPP-modified liposomes; multifunctional liposomes. - Micelles: polymeric micelles; lipid-core micelles based on PEG-phosphatidylethanolamine (PEG-PE); PVP-lipid micelles; mixed micelles; targeted micelles; immunomicelles; stimuli-responsive micelles; diagnostic micelles. - Payloads: poorly water-soluble drugs (paclitaxel, doxorubicin, tamoxifen, camptothecin, porphyrins), platinum drugs, cyclosporin A, antisense oligonucleotides, siRNA, DNA, antigens, and imaging/contrast agents. - Targeting ligands: monoclonal antibodies and fragments, transferrin, folate, RGD peptides, VIP, galactose/lactose, and TAT cell-penetrating peptide. - Stimuli: pH, temperature, and ultrasound. - Imaging agents: Gd, Mn, Dy chelates; 111In; iodine-containing polymers; fluorescent labels.

Approach: Review and synthesis of preclinical and clinical literature. Model systems include various tumor cell lines (MCF-7, HeLa, BT-20, A2780, PC-3, C6 glioma), murine tumor models (Lewis lung carcinoma, EL4 lymphoma, B16 melanoma), myocardial infarction in rabbits, and human clinical trials. Clinical products discussed include DOXIL/Caelyx, AmBisome, Myocet, DaunoXome, SPI-077, Lipoflatin, and others. As a review, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The review discusses data generated by cited studies using: - Pharmacokinetics, biodistribution, and blood clearance measurements. - Fluorescence microscopy and labeled micelle/liposome tracking. - MRI, gamma-scintigraphy, CT, and ultrasound imaging. - In vitro cytotoxicity (IC50) and cell-killing assays. - ELISA and SDS-PAGE for ligand/antibody attachment. - Tumor accumulation and therapeutic efficacy studies. - Clinical trial safety and efficacy readouts.

Key results: Conventional liposomes: 50–80% of dose is captured by RES within 15–30 min after IV administration. - PEGylated liposomes: circulation half-life >20 h, with only 10–15% of dose captured by liver. - Micelles: typical size 5–100 nm; pharmaceutical micelles often 10–80 nm; drug loading ideally 5–25 wt%. - PEG-PE micelles: size 7–35 nm; retain >90% of encapsulated drug after 7 h dialysis; tumor accumulation peaks at 3–5 h. - In A2780 ovarian carcinoma cells, paclitaxel IC50 was 22.5 µM for free drug, 5.8 µM for PEG-PE micelles, and 1.2 µM for PEG-PE/Lipofectin mixed micelles. - Antibody-modified immunomicelles improved tumor accumulation and killing versus nontargeted micelles. - Diagnostic micelles enabled 3–4-fold X-ray blood pool enhancement for at least 2 h in rats and rabbits. - Several liposomal drugs reached market or clinical trials, including DOXIL/Caelyx, AmBisome, Myocet, and DaunoXome.

Interpretation: The authors conclude that liposomes and micelles are versatile lipid-based nanocarriers capable of improving drug solubility, circulation, targeting, stimuli-responsive release, intracellular delivery, and imaging. They argue that combining multiple functions in one nanocarrier—longevity, targeting, stimuli-sensitivity, and contrast properties—will enhance therapeutic and diagnostic efficacy and lead to broader clinical applications.

Limitations: Review article; no primary data, effect sizes, n values, doses, or controls. - Not a systematic review or meta-analysis. - Most cited studies are preclinical; clinical data remain limited. - EPR-mediated passive targeting is heterogeneous across tumors and pathological sites. - Complex multifunctional formulations face scale-up, stability, manufacturing, and regulatory challenges. - Long-term safety, immunogenicity, and repeated-dose effects are not fully established. - PEGylation can reduce cellular uptake and may induce anti-PEG immune responses. - Intracellular delivery and endosomal escape remain inefficient for many payloads.